This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion ( compared to placebo), 250mcg/day on majore outcomes up to 6 months after randomization in participants with advanced HF with reduced ejection fraction(HFrEF).
Patients older than 18 years of age, of any gender/sex and race/ethnicity
most recent LVEF( by conventional imaging method<30% which was mwasured within 3 months prior randomization.
Nt-proBNP >1500 ng/L or BNP >300 ng/L at prior randomization
New York Heart Association (NYHA) functional class IIIb or IV, i.e., chronic dyspnoea or fatigue at rest or with minimal exertion for at least one month prior to consent.
None
Biopeutics Co., Ltd
Lead sponsor